Imagion Biosystems Ltd (IBXXF)

[Hncher]

Biotech company Imagion lists on the ASX after AU$12m IPO

http://www.zdnet.com/article/biotech-company-imagion-lists-on-the-asx-after-au12m-ipo/

Imagion CEO Robert Proulx said the magnetic sensors are 1,000 times more sensitive than conventional imaging methods -- it is able to detect tumours that are 1 millimetre in diameter -- and comes at a lower cost.

"The use of cancer-tagging nanoparticles allows the instrument to be of a relatively simple and low cost design, and unlike other less sensitive imaging methods such as MRI, CT, or PET, the MagSense system does not require an expensive shielded environment, translating into lower installation costs for the hospital or clinic," the company stated in a disclosure to the Australian Securities Exchange (ASX).

Magsense is also a non-invasive alternative to procedures such as biopsies as patients are administered with a low dose of cancer specific nanoparticles via intravenous injection, then positioned under the detector, after which the nanoparticles are briefly magnetised and detected.

"Additionally, from a business case perspective, having both the measuring instrument and the cancer specific nanoparticles is akin to a 'printer and ink' scenario, providing a high gross margin recurring source of revenue on the installed base of MagSense machines," the company said.

Imagion believes its technology will optimise patient care and reduce mortality rates across various cancer indications.